JP2015536964A - Ｂ−ｒａｆ阻害剤とヒストン脱アセチル化酵素阻害剤を含む医薬組合せおよび増殖性疾患の治療におけるそれらの使用 - Google Patents
Ｂ−ｒａｆ阻害剤とヒストン脱アセチル化酵素阻害剤を含む医薬組合せおよび増殖性疾患の治療におけるそれらの使用 Download PDFInfo
- Publication number
- JP2015536964A JP2015536964A JP2015541167A JP2015541167A JP2015536964A JP 2015536964 A JP2015536964 A JP 2015536964A JP 2015541167 A JP2015541167 A JP 2015541167A JP 2015541167 A JP2015541167 A JP 2015541167A JP 2015536964 A JP2015536964 A JP 2015536964A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- raf
- histone deacetylase
- inhibitor
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)[n](cc1-c2ccnc(*C=C(C)NC(OC)=O)n2)nc1-c1c(*s(C)([n]2)=O)c2cc(*)c1 Chemical compound CC(C)[n](cc1-c2ccnc(*C=C(C)NC(OC)=O)n2)nc1-c1c(*s(C)([n]2)=O)c2cc(*)c1 0.000 description 1
- QJQLZJSVUBZTRT-AWEZNQCLSA-N CC(C)[n](cc1-c2nc(NC[C@H](C)NC(OC)=O)ncc2C)nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F Chemical compound CC(C)[n](cc1-c2nc(NC[C@H](C)NC(OC)=O)ncc2C)nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F QJQLZJSVUBZTRT-AWEZNQCLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723925P | 2012-11-08 | 2012-11-08 | |
| US61/723,925 | 2012-11-08 | ||
| PCT/EP2013/073452 WO2014072493A1 (en) | 2012-11-08 | 2013-11-08 | Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015536964A true JP2015536964A (ja) | 2015-12-24 |
| JP2015536964A5 JP2015536964A5 (enExample) | 2016-12-15 |
Family
ID=49552384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015541167A Pending JP2015536964A (ja) | 2012-11-08 | 2013-11-08 | Ｂ−ｒａｆ阻害剤とヒストン脱アセチル化酵素阻害剤を含む医薬組合せおよび増殖性疾患の治療におけるそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150283136A1 (enExample) |
| EP (1) | EP2916834A1 (enExample) |
| JP (1) | JP2015536964A (enExample) |
| CN (1) | CN104994850A (enExample) |
| AU (1) | AU2013343425A1 (enExample) |
| BR (1) | BR112015010477A2 (enExample) |
| CA (1) | CA2890663A1 (enExample) |
| HK (1) | HK1214765A1 (enExample) |
| RU (1) | RU2015121367A (enExample) |
| UA (1) | UA115151C2 (enExample) |
| WO (1) | WO2014072493A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| JP6150813B2 (ja) | 2011-11-11 | 2017-06-21 | ノバルティス アーゲー | 増殖性疾患の治療方法 |
| CA2856406C (en) | 2011-11-23 | 2020-06-23 | Novartis Ag | Pharmaceutical formulations |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| PL3099717T3 (pl) | 2014-01-31 | 2019-10-31 | Novartis Ag | Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie |
| EA201691765A1 (ru) | 2014-03-14 | 2016-12-30 | Новартис Аг | Молекулы антител против lag-3 и их применения |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| TWI706958B (zh) | 2015-03-10 | 2020-10-11 | 美商艾杜諾生物科技公司 | 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法 |
| US10729669B2 (en) | 2015-07-28 | 2020-08-04 | University Of Iowa Research Foundation | Compositions and methods for treating cancer |
| US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| US20180340025A1 (en) | 2015-07-29 | 2018-11-29 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| WO2017058007A1 (en) | 2015-10-01 | 2017-04-06 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma |
| PT3370768T (pt) | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| AU2017281940C1 (en) | 2016-06-24 | 2024-11-07 | University Of Iowa Research Foundation | Compositions and methods of treating melanoma |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
| US11529335B2 (en) | 2020-07-31 | 2022-12-20 | University Of Iowa Research Foundation | Compositions and methods for treating cancer |
| WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
| WO2025003956A1 (en) | 2023-06-30 | 2025-01-02 | Pfizer Inc. | High drug loading formulations of encorafenib |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EA200600495A1 (ru) * | 2003-09-23 | 2006-10-27 | Новартис Аг | Комбинация ингибитора vegf рецептора с химиотерапевтическим агентом |
| PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| JO3002B1 (ar) * | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| HUE032100T2 (en) * | 2011-03-21 | 2017-08-28 | Valcuria Ab | A pharmaceutical composition comprising an HDAC inhibitor and a steroid and its use |
| CN103608012A (zh) * | 2011-06-14 | 2014-02-26 | 诺华股份有限公司 | 在癌症如骨髓增殖性肿瘤治疗中的帕比司他与鲁索利替尼的组合 |
-
2013
- 2013-11-08 HK HK16102742.9A patent/HK1214765A1/zh unknown
- 2013-11-08 WO PCT/EP2013/073452 patent/WO2014072493A1/en not_active Ceased
- 2013-11-08 AU AU2013343425A patent/AU2013343425A1/en not_active Abandoned
- 2013-11-08 EP EP13788784.0A patent/EP2916834A1/en not_active Withdrawn
- 2013-11-08 CA CA2890663A patent/CA2890663A1/en not_active Abandoned
- 2013-11-08 BR BR112015010477A patent/BR112015010477A2/pt not_active IP Right Cessation
- 2013-11-08 RU RU2015121367A patent/RU2015121367A/ru not_active Application Discontinuation
- 2013-11-08 JP JP2015541167A patent/JP2015536964A/ja active Pending
- 2013-11-08 CN CN201380063549.9A patent/CN104994850A/zh active Pending
- 2013-11-08 UA UAA201505166A patent/UA115151C2/uk unknown
- 2013-11-08 US US14/441,750 patent/US20150283136A1/en active Granted
Non-Patent Citations (1)
| Title |
|---|
| LAI, FRITZ ET AL.: "Histone Deacytylases(HDACs) as Mediators of Resistance to Apoptosis in Melanoma and as Targets for C", ADVANCES IN PHARMACOLOGY, vol. 65, JPN6017026965, 6 September 2012 (2012-09-06), pages 27 - 43, ISSN: 0003750444 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104994850A (zh) | 2015-10-21 |
| AU2013343425A1 (en) | 2015-06-11 |
| CA2890663A1 (en) | 2014-05-15 |
| BR112015010477A2 (pt) | 2017-07-11 |
| EP2916834A1 (en) | 2015-09-16 |
| RU2015121367A (ru) | 2017-01-10 |
| US20150283136A1 (en) | 2015-10-08 |
| HK1214765A1 (zh) | 2016-08-05 |
| WO2014072493A1 (en) | 2014-05-15 |
| UA115151C2 (uk) | 2017-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104994850A (zh) | 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途 | |
| US12036227B2 (en) | Combination therapy | |
| US11413258B2 (en) | Methods for treating cancer | |
| CA2874860C (en) | Pharmaceutical combinations of a cdk4/6 inhibitor and a b-raf inhibitor | |
| KR102418765B1 (ko) | 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법 | |
| CN103764144B (zh) | Pi3k抑制剂与mek抑制剂的协同组合 | |
| TW202214242A (zh) | 西奧羅尼或其衍生物在製備用於預防和/或治療非霍奇金淋巴瘤的藥物之用途 | |
| EP4106756A1 (en) | Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc | |
| US11406627B2 (en) | Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers | |
| US12551471B2 (en) | ABT-751 and ionizing radiation | |
| JP7818502B2 (ja) | 胃腸間質腫瘍を治療するためのリプレチニブ | |
| RU2815400C2 (ru) | Комбинированная терапия | |
| TW202435890A (zh) | Raf抑制劑及kras g12c抑制劑組合療法 | |
| Alimova et al. | ATRT-07. AN EPIGENOME DIRECTED FUNCTIONAL GENOMIC SCREEN IDENTIFIES SIRT2 AS A SYNTHETIC LETHAL TARGET IN SMARCB1 DEFICIENT ATRT | |
| BR112014033118B1 (pt) | Combinações farmacêuticas de um inibidor de cdk4/6 e um inibidor de braf, e seus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161024 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161024 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170725 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180306 |